We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant porcine factor VIII use in bleed treatment in non‐severe haemophilia A inhibitor patients: Dosing strategies and efficacy.
- Authors
Ellsworth, Patrick; Chen, Sheh‐Li; Key, Nigel; Abajas, Yasmina; Ma, Alice
- Abstract
The development of alloantibodies to factor VIII remains a significant complication in the treatment of patients with congenital haemophilia A (cHA). Bleeding patterns in roughly 2/3 of patients are similar to patients with AHA, including severe, life-threatening bleeding. Haemostasis was achieved in all patients with no treatment-related adverse effects, despite one patient having an initially detectable antiporcine FVIII inhibitor titre (pBIA), and 2 of 5 developing pBIA during or after treatment. While our paediatric patient required very frequent dosing resulting in high cumulative utilization of rpFVIII, he was also the only patient with an initially detectable porcine inhibitor, and the only patient with a high-titre pBIA, though 2 of the adults had high-titre hBIA.
- Subjects
HEMOPHILIA; BLOOD coagulation factor VIII antibodies; CHILD patients; HEMORRHAGE
- Publication
Haemophilia, 2021, Vol 27, Issue 1, pe147
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14111